Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis
Abstract Background Cervical cancer is a major concern to women’s health, being the fourth most common cancer worldwide. A great percentage of these cancer is consequence of an HPV infection, namely from specific genotypes such as 16/18. Portuguese screening program subjects women to a reflex cytolo...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-03-01
|
| Series: | BMC Women's Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12905-023-02219-0 |
| _version_ | 1827326366857560064 |
|---|---|
| author | Daniel Figueiredo Inês Ribeiro Ana Penedones Diogo Mendes Carlos Alves Francisco Batel-Marques Daniel Pereira da Silva |
| author_facet | Daniel Figueiredo Inês Ribeiro Ana Penedones Diogo Mendes Carlos Alves Francisco Batel-Marques Daniel Pereira da Silva |
| author_sort | Daniel Figueiredo |
| collection | DOAJ |
| description | Abstract Background Cervical cancer is a major concern to women’s health, being the fourth most common cancer worldwide. A great percentage of these cancer is consequence of an HPV infection, namely from specific genotypes such as 16/18. Portuguese screening program subjects women to a reflex cytology triage every 5 years. Aptima® HPV is a screening test which presents better specificity than other tests which are used in Portugal (Hybrid Capture® 2 and Cobas® 4800) and still have a comparable sensitivity. The present study aims to estimate the number of diagnostic tests and costs that are avoided using Aptima® HPV compared to the use of two other tests, Hybrid Capture® 2 and Cobas® 4800, within the cervical cancer screening programme in Portugal. Methods A model, consisting of a decision-tree, was developed to represent the full Portuguese screening program for cervical cancer. This model is used to compare the costs resulting from using Aptima® HPV test versus the other tests used in Portugal, during 2 years. Other outcomes such as the number of additional tests and exams were also computed. This comparison considers the performance of each test (sensitivity and specificity) and assumes an equal price for every test compared. Results Cost savings resulting from the use of Aptima® HPV are estimated at approximately €382 million versus Hybrid Capture® 2 and €2.8 million versus Cobas® 4800. Moreover, Aptima® HPV prevents 265,443 and 269,856 additional tests and exams when compared with Hybrid Capture® 2 and Cobas® 4800. Conclusions The use of Aptima® HPV resulted in lower costs as well as less additional test and exams. These values result from the greater specificity of Aptima® HPV, which signals less false positive cases and consequently avoids carrying out additional tests. |
| first_indexed | 2024-03-07T14:43:25Z |
| format | Article |
| id | doaj.art-29921ae26a2049e5971354ab3d5fadc4 |
| institution | Directory Open Access Journal |
| issn | 1472-6874 |
| language | English |
| last_indexed | 2024-03-07T14:43:25Z |
| publishDate | 2023-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Women's Health |
| spelling | doaj.art-29921ae26a2049e5971354ab3d5fadc42024-03-05T20:08:20ZengBMCBMC Women's Health1472-68742023-03-0123111210.1186/s12905-023-02219-0Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysisDaniel Figueiredo0Inês Ribeiro1Ana Penedones2Diogo Mendes3Carlos Alves4Francisco Batel-Marques5Daniel Pereira da Silva6Association for Innovation and Biomedical Research on Light and ImageLaboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of CoimbraLaboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of CoimbraLaboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of CoimbraLaboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of CoimbraLaboratory of Social Pharmacy and Public Health, Faculty of Pharmacy, University of CoimbraCUF Coimbra HospitalAbstract Background Cervical cancer is a major concern to women’s health, being the fourth most common cancer worldwide. A great percentage of these cancer is consequence of an HPV infection, namely from specific genotypes such as 16/18. Portuguese screening program subjects women to a reflex cytology triage every 5 years. Aptima® HPV is a screening test which presents better specificity than other tests which are used in Portugal (Hybrid Capture® 2 and Cobas® 4800) and still have a comparable sensitivity. The present study aims to estimate the number of diagnostic tests and costs that are avoided using Aptima® HPV compared to the use of two other tests, Hybrid Capture® 2 and Cobas® 4800, within the cervical cancer screening programme in Portugal. Methods A model, consisting of a decision-tree, was developed to represent the full Portuguese screening program for cervical cancer. This model is used to compare the costs resulting from using Aptima® HPV test versus the other tests used in Portugal, during 2 years. Other outcomes such as the number of additional tests and exams were also computed. This comparison considers the performance of each test (sensitivity and specificity) and assumes an equal price for every test compared. Results Cost savings resulting from the use of Aptima® HPV are estimated at approximately €382 million versus Hybrid Capture® 2 and €2.8 million versus Cobas® 4800. Moreover, Aptima® HPV prevents 265,443 and 269,856 additional tests and exams when compared with Hybrid Capture® 2 and Cobas® 4800. Conclusions The use of Aptima® HPV resulted in lower costs as well as less additional test and exams. These values result from the greater specificity of Aptima® HPV, which signals less false positive cases and consequently avoids carrying out additional tests.https://doi.org/10.1186/s12905-023-02219-0Early detection of cancerPapillomavirus infectionsCervical cancerCosts and cost analysis |
| spellingShingle | Daniel Figueiredo Inês Ribeiro Ana Penedones Diogo Mendes Carlos Alves Francisco Batel-Marques Daniel Pereira da Silva Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis BMC Women's Health Early detection of cancer Papillomavirus infections Cervical cancer Costs and cost analysis |
| title | Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
| title_full | Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
| title_fullStr | Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
| title_full_unstemmed | Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
| title_short | Performance of Aptima-HPV in the cervical cancer screening program of Portugal: a cost-analysis |
| title_sort | performance of aptima hpv in the cervical cancer screening program of portugal a cost analysis |
| topic | Early detection of cancer Papillomavirus infections Cervical cancer Costs and cost analysis |
| url | https://doi.org/10.1186/s12905-023-02219-0 |
| work_keys_str_mv | AT danielfigueiredo performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis AT inesribeiro performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis AT anapenedones performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis AT diogomendes performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis AT carlosalves performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis AT franciscobatelmarques performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis AT danielpereiradasilva performanceofaptimahpvinthecervicalcancerscreeningprogramofportugalacostanalysis |